In:
Blood, American Society of Hematology, Vol. 130, No. 6 ( 2017-08-10), p. 789-802
Kurzfassung:
BM stroma-derived conditions protect AML patient cells against topoisomerase II and BCL2 inhibitors, as well as several classes of TKIs. JAK1/2 inhibitor ruxolitinib reverses cytoprotection against BCL2 antagonist venetoclax, suggesting a novel combinatorial treatment.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2016-02-699363
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2017
ZDB Id:
1468538-3
ZDB Id:
80069-7